Drug and Therapeutics Bulletin 1997;35:36-37; doi:10.1136/dtb.1997.35536
Copyright © 1997 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Aminoglycosides once daily?

Relevant BNF section: 5.1.4

Six aminoglycosides (amikacin, gentamicin, kanamycin, netilmicin, streptomycin and tobramycin) are licensed for parenteral use in the UK. As a group, they remain effective against infections caused by aerobic gram-negative organisms and Staphylococcus aureus, including species commonly resistant to beta-lactam antibiotics. However, their use is limited by the severity of their unwanted effects and by their route and frequency of administration; traditionally, they have been given intravenously two to four times daily. Increasingly, they are being given once daily in an attempt to simplify treatment without reducing efficacy or increasing toxicity.^1,2 Here we evaluate the advantages and disadvantages of this once-daily approach.

This article has been cited by other articles:

				A. Whitehead, S.P. Conway, C. Etherington, N.A. Caldwell, N. Setchfield, and S. Bogle Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Eur. Respir. J., February 1, 2002; 19(2): 303 - 309. [Abstract] [Full Text] [PDF]